Molecular biology of renal cell cancer and the identification of therapeutic targets

Journal of Clinical Oncology

Volumn 24, Issue 35, 2006, Pages 5593-5600

  Iliopoulos, Othon ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARATE HYDRATASE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; SCATTER FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRICARBOXYLIC ACID; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN; VHL PROTEIN, HUMAN;

ANGIOGENESIS; BIRT HOGG DUBE SYNDROME; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LEIOMYOMATOSIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE; DRUG ANTAGONISM; GENETICS; KIDNEY TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

CARCINOMA, RENAL CELL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; KIDNEY NEOPLASMS; SIGNAL TRANSDUCTION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 34247385849     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.8948     Document Type: Review

References (109)

1. Motzer RJ, Bander NH, Nanus DM: Renal cell carcinoma. N Engl J Med 335:865-875, 1996
2. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 353:2477-2490, 2005
3. Lonser RR, Glenn GM, Walther M, et al: Von Hippel-Lindau disease. Lancet 361:2059-2067, 2003
4. Maher ER, Yates JRW, Harries R, et al: Clinical features and natural history of von Hippel-Lindau Disease. Q J Med 77:1151-1163, 1990
5. Latif F, Tory K, Gnarra J, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320, 1993
6. Iliopoulos O, Kibel A, Gray S, et al: Tumor suppression by the human von Hippel-Lindau gene product. Nat Med 1:822-826, 1995
7. Iliopoulos O, Ohh M, Kaelin W: PVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci U S A 95:11661-11666, 1998
8. Stickle NH, Chung J, Klco JM, et al: PVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol 24:3251-3261, 2004
9. Stolle C, Glenn G, Zbar B, et al: Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12:417-423, 1998
10. Prowse A, Webster A, Richards F, et al: Somatic inactivation of the VHL gene in Von HippelLindau disease tumors. Am J Hum Genet 60:765-771, 1997
11. Lubensky IA, Gnarra JR, Bertheau P, et al: Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 149:2089-2094, 1996
12. Gnarra JR, Zhou S, Merrill MJ, et al: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumor suppressor gene product. Proc Natl Acad Sci U S A 93:10589-10594, 1996
13. Gnarra JR, Tory K, Weng Y, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90, 1994
14. Shuin T, Kondo K, Torigoe S, et al: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54:2852-2855, 1994
15. Kibel A, Iliopoulos O, DeCaprio JD, et al: Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269:1444-1446, 1995
16. Duan DR, Pause A, Burgress W, et al: Inhibition of transcriptional elongation by the VHL tumor suppressor protein. Science 269:1402-1406, 1995
17. Conaway JW, Kamura T, Conaway RC: The Elongin BC complex and the von Hippel-Lindau tumor suppressor protein. Biochim Biophys Acta 1377:M49-54, 1998
18. Lonergan KM, Iliopoulos O, Ohh M, et al: Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 18:732-741, 1998
19. Lisztwan J, Imbert G, Wirbelauer C, et al: The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 13:1822-1833, 1999
20. Stebbins CE, Kaelin WG, Pavletich NP: Structure of the VHL-elonginC-elonginB complex: Implications for VHL tumor suppressor function. Science 284:455-461, 1999
21. Maxwell PH, Wiesener MS, Chang GW, et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275, 1999
22. Ohh M, Park CW, Ivan M, et al: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2:423-427, 2000
23. Semenza GL: HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13:167-171, 2001
24. Jaakkola P, Mole D, Tian YM, et al: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468-472, 2001
25. Ivan M, Kondo K, Yang H, et al: HIF1a targeted for VHL-mediated destruction by proline hydroxylation: Implications for oxygen sensing. Science 292:464-468, 2001
26. Epstein AC, Gleadle JM, McNeill LA, et al: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54, 2001
27. Ivan M, Haberberger T, Gervasi DC, et al: Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A 99:13459-13464, 2002
28. Schofield C, Ratcliffe P: Oxygen sensing by the HIF hydroxylases. Nature Reviews Molecular Cell Biology 5:343-354, 2004
29. Giaccia AJ, Simon MC, Johnson R: The biology of hypoxia: The role of oxygen sensing in development, normal function, and disease. Genes Dev 18:2183-2194, 2004
30. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996
31. Harris AL: Hypoxia: A key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47, 2002
32. Veikkola T, Alitalo K: VEGFs, receptors and angiogenesis. Semin Cancer Biol 9:211-220, 1999
33. Saaristo A, Karpanen T, Alitalo K: Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 19:6122-6129, 2000
34. Dibb MJ, Dilworth SM, Mol CD: Switching on kinases: Oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer 4:718-727, 2004
35. Bjarnegard M, Enge M, Norlin J, et al: Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities. Development 131:1847-1857, 2004
36. Lindblom P, Gerhardt H, Liebner S, et al: Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 17:1835-1840, 2003
37. Erler JT, Bennewith KL, Nicolau M, et al: Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222-1226, 2006
38. Ananth S, Knebelmann B, Gruning W, et al: Transforming growth factor betal is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 59:2210-2216, 1999
39. Staller P, Sulitkova J, Lisztwan J, et al: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425:307-311, 2003
40. Esteban MA, Tran MG, Harten SK, et al: Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 66:3567-3575, 2006
41. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454, 2002
42. Chen F, Kishida T, Yao M, et al: Germline mutations in the Von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Hum Mutat 5:66-75, 1995
43. Crossey PA, Richards FM, Foster K, et al: Identification of intragenic mutations in the von Hippel-Lindau disease tumor suppressor gene and correlation with disease phenotype. Hum Mol Genet 3:1303-1308, 1994
44. Hoffman MA, Ohh M, Yang H, et al: Von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10:1019-1027, 2001
45. Clifford SC, Cockman ME, Smallwood A, et al: Contrasting effects on HIF1a regulation by disease-causing pVHL mutations correlate with patterns of tumorigenesis in von Hippel-Lindau disease. Hum Mol Genet 10:1029-1038, 2001
46. Knauth K, Bex C, Jemth P, et al: Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1 alpha interactions. Oncogene 25:370-377, 2006
47. Maranchie JK, Vasselli JR, Riss J, et al: The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1:247-255, 2002
48. Kondo K, Klco J, Nakamura E, et al: Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1:237-246, 2002
49. Kondo K, Kim WY, Lechpammer M, et al: Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1:83, 2003
50. Zimmer M, Doucette D, Siddiqui N, et al: Inhibition of hypoxia inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2:89-95, 2004
51. Rankin EB, Higgins DF, Walisser JA, et al: Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol 25:3163-3172, 2005
52. Hay N: The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8:179-183, 2005
53. Ito N, Rubin GM: Gigas, a drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle. Cell 96:529-539, 1999
54. Tapon N, Ito N, Dickson BJ, et al: The drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105:345-355, 2001
55. Potter CJ, Pedraza LG, Xu T: Akt regulates growth by directly phosphorylating TSC2. Nat Cell Biol 4:658-665, 2002
56. Gao X, Zhang Y, Arrazola P, et al: Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 4:699-704, 2002
57. Inoki K, Li Y, Zhu T, et al: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648-657, 2002
58. Brugarolas JB, Vazquez F, Reddy A, et al: TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4:147-158, 2003
59. Brugarolas J, Lei K, Hurley RL, et al: Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18:2893-2904, 2004
60. Mabjeesh NJ, Post DE, Willard MT, et al: Geldanamycin induces degradation of hypoxia-inducible factor 1 alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62:2478-2482, 2002
61. Mabjeesh N, Escuin D, LaVallee T, et al: 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3:363-375, 2003
62. Lin S, Tsai SC, Lee CC, et al: Berberine inhibits HIF-1alpha expression via enhanced proteolysis. Mol Pharmacol 66:612-619, 2004
63. Rapisarda A, Uranchimeg B, Scudiero DA, et al: Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62:4316-4324, 2002
64. Rapisarda A, Zalek J. Hollingshead M, et al: Schedule-dependent inhibition of hypoxia-inducible factor-1 alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64:6845-6848, 2004
65. Rapisarda A, Uranchimeg B, Sordet O, et al: Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications. Cancer Res 64:1475-1482, 2004
66. Yeo EJ, Chun YS, Cho YS, et al: YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95:516-525, 2003
67. Welsh S, Williams R, Kirkpatrick L, et al: Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1 alpha. Mol Cancer Ther 3:233-244, 2004
68. Thomas GV, Tran C, Mellinghoff IK, et al: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127, 2006
69. Kung AL, Wang S, Klco JM, et al: Suppression of tumor growth disruption of hypoxia-inducible transcription. Nat Med 6:1335-1340, 2000
70. Kuznetsova AV, Meller J, Schnell PO, et al: Von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc Natl Acad Sci U S A 100:2706-2711, 2003
71. Na X, Duan HO, Messing EM, et al: Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J 22:4249-4259, 2003
72. Ohh M, Yauch RL, Lonergan KM, et al: The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1:959-968, 1998
73. Tang N, Mack F, Haase VH, et al: PVHL function is essential for endothelial extracellular matrix deposition. Mol Cell Biol 26:2519-2530, 2006
74. Roe JS, Kim H, Lee SM, et al: p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 22:395-405, 2006
75. Reuter VE, Presti JC: Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 27:124-137, 2000
76. Zbar B, Lerman M: Inherited carcinomas of the kidney. Adv Cancer Res 75:163-201, 1998
77. Duh FM, Scherer SW, Tsui LC, et al: Gene structure of the human MET proto-oncogene. Oncogene 15:1583-1586, 1997
78. Bardelli A, Ponzetto C, Comoglio PM: Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. J Biotechnol 37:109-122, 1994
79. Bottaro DP, Rubin JS, Faletto DL, et al: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802-804, 1991
80. Ponzetto C, Bardelli A, Zhen Z, et al: A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77:261 -271, 1994
81. Boccaccio C, Comoglio PM: Invasive growth: A MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6:637-645, 2006
82. Giordano S, Zhen Z, Medico E, et al: Transfer of mitogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene. Proc Natl Acad Sci U S A 90:649-653, 1993
83. Comoglio PM: Pathway specificity for Met signalling. Nat Cell Biol 3:E161-E162, 2001
84. Giordano S, Corso S, Conrotto P, et al: The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 4:720-724, 2002
85. Schmidt L, Duh FM, Chen F, et al: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73, 1997
86. Schmidt L, Junker K, Nakaigawa N, et al: Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18:2343-2350, 1999
87. Sanders ME, Mick R, Tomaszewski JE, et al: Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma. Am J Pathol 161:997-1005, 2002
88. Sweeney P, El-Naggar AK, Lin SH, et al: Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol 168:51-55, 2002
89. Morris MR, Gentle D, Abdulrahman M, et al: Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res 65:4598-4606, 2005
90. Pennacchietti S, Michieli P, Galluzzo M, et al: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347-361, 2003
91. Koochekpour S, Jeffers M, Wang PH, et al: The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 19:5902-5912, 1999
92. Christensen JG, Schreck R, Burrows J, et al: A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63:7345-7355, 2003
93. Sattler M, Pride YB, Ma P, et al: A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 63:5462-5469, 2003
94. Burgess T, Coxon A, Meyer S: Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 66:1721-1729, 2006
95. Launonen V, Vierimaa O, Kiuru M, et al: Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 98:3387-3392, 2001
96. Consortium TML: Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:306-310, 2002
97. Alam NA, Olpin S, Leigh IM: Fumarate hydratase mutations and predisposition to cutaneous leiomyomas, uterine leiomyomas and renal cancer. Br J Dermatol 153:11-17, 2005
98. Lehtonen R, Kiuru M, Vanharanta S, et al: Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol 164:17-22, 2004
99. Morris MR, Maina E, Morgan NV, et al: Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. J Clin Pathol 57:706-711, 2004
100. Isaacs JS, Jung YJ, Mole DR, et al: HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell 8:143-153, 2005
101. Selak MA, Armour SM, Mackenzie ED, et al: Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7:77-85, 2005
102. Birt AR, Hogg GR, Dube WJ: Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 113:1674-1677, 1977
103. Nickerson ML, Warren MB, Toro JR, et al: Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2:157-164, 2002
104. Zbar B, Alvord WG, Glenn G, et al: Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev 11:393-400, 2002
105. Toro JR, Glenn G, Duray P, et al: Birt-Hogg-Dube syndrome: A novel marker of kidney neoplasia. Arch Dermatol 135:1195-1202, 1999
106. Roth JS, Rabinowitz AD, Benson M, et al: Bilateral renal cell carcinoma in the Birt-Hogg-Dube syndrome. J Am Acad Dermatol 29:1055-1056, 1993
107. Khoo SK, Bradley M, Wong FK, et al: Birt-Hogg-Dube syndrome: Mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2. Oncogene 20:5239-5242, 2001
108. Schmidt LS, Warren MB, Nickerson ML, et al: Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 69:876-882, 2001
109. Vocke CD, Yang Y, Pavlovich CP, et al: High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors. J Natl Cancer Inst 97:931-935, 2005